Journal
PHARMACEUTICAL RESEARCH
Volume 34, Issue 8, Pages 1544-1550Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-017-2128-0
Keywords
biomarkers; clinical uptake; diagnostic tests; personalized medicine
Ask authors/readers for more resources
Pharmacogenetic testing aims to personalize drug therapy with a view to optimising drug efficacy and minimise toxicity. However, despite the potential benefits, pharmacogenetic testing is mostly confined to specialised medical areas, laboratories and centres. Widespread integration into routine clinical practice has been limited by a complex set of issues including regulatory and reimbursement frameworks, evidence of clinical utility and clinician perspectives, practices and education. Here we assess the current barriers to widespread clinical uptake and identify the key issue necessary to address to accelerate routine testing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available